<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876343</url>
  </required_header>
  <id_info>
    <org_study_id>031-08-001</org_study_id>
    <secondary_id>JapicCTI-090724</secondary_id>
    <nct_id>NCT00876343</nct_id>
  </id_info>
  <brief_title>Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder</brief_title>
  <official_title>Placebo-Controlled, Double-Blind, Parallel Group-Comparison Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy
      co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a
      serotonin-norepinephrine reuptake inhibitor (SNRI) in patients with major depressive
      disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Baseline (the end of the SSRI/SNRI treatment period), at completion of administration</time_frame>
    <description>The change in MADRS total score from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period by covariance analysis, and compared the aripiprazole variable dose group with the placebo group as well as the aripiprazole fixed dose group with the placebo group.
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.
The questionnaire includes questions on the following symptoms
1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MADRS Response Rate</measure>
    <time_frame>Baseline (the end of the SSRI/SNRI treatment period), at completion of administration</time_frame>
    <description>The percentage of subjects with a decrease in MADRS total score of 50% or more, from the end of the SSRI/SNRI treatment period to the end of the placebo-controlled, double-blind treatment period (or withdrawal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Sheehan Disability Scale (SDISS)</measure>
    <time_frame>Baseline (the end of the SSRI/SNRI treatment period), at completion of administration</time_frame>
    <description>The endpoint evaluated the change in SDISS from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period.
The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">586</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titration dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole (Fixed dose)</intervention_name>
    <description>administered orally once daily, 3 mg daily, 6 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Aripiprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole (Titrated dose)</intervention_name>
    <description>administered orally once daily, 3 to 15 mg daily, 6 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Aripiprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administered orally once daily, 6 weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Placebo of aripiprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are either inpatients or outpatients

          2. Patients who have the ability to understand and to provide informed consent to the
             examination, observation, and evaluation processes specified in this protocol, and
             have signed the informed consent form based on a full understanding of the trial

          3. Patients diagnosed as having either &quot;296.2x Major Depressive Disorder, Single Episode&quot;
             or &quot;296.3x Major Depressive Disorder, Recurrent&quot; according to DSM-IV-TR, and for whom
             the current episode of major depressive disorder has been ongoing for more than 8
             weeks

          4. Patients with a HAM-D17 total score of 18 or more

        Exclusion Criteria:

          1. Female patients of child bearing potential who wish to become pregnant during the
             treatment period, or within 4 weeks after study completion/discontinuation

          2. Female patients who are pregnant, possibly pregnant, or breast feeding

          3. Patients judged to be unable to tolerate any type of antidpressant treatment
             (including drugs not being used in the current episode of major depressive disorder),
             based on treatment history to date

          4. Patients who have previously received electro-convulsive therapy

          5. Patients who have participated in clinical studies on medical devices or other drugs
             within the past month

          6. Patients at risk of having serious adverse events or developing symptoms that could
             interfere with safety and efficacy evaluations (such as symptoms of fibromyalgia
             syndrome overlapping with symptoms of depression), based on previous medical history

          7. Patients with a history or a complication of diabetes

          8. Patients with thyroid disease (excluding patients who are stabilized on drug therapy
             for at least 3 months)

          9. Patients with a history of serotonin syndrome or psychotropic neuroleptic malignant
             syndrome

         10. Patients with a history of seizure disorder (epilepsy etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsuhisa Saito</last_name>
    <role>Study Director</role>
    <affiliation>OPC-J</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinki Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2009</study_first_posted>
  <results_first_submitted>December 20, 2013</results_first_submitted>
  <results_first_submitted_qc>December 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2014</results_first_posted>
  <last_update_submitted>December 20, 2013</last_update_submitted>
  <last_update_submitted_qc>December 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Variable Dose Group of Aripiprazole</title>
          <description>Aripiprazole 3~15 mg were administered orally once daily. During the first week, 3 mg was administered once daily. Thereafter, each week, a dose increase of 3 mg per day was carried out</description>
        </group>
        <group group_id="P2">
          <title>Fixed Dose Group of Aripiprazole</title>
          <description>Aripiprazole 3 mg were administered orally once daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo Group</title>
          <description>Placebo were administered orally once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="197"/>
                <participants group_id="P3" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="180"/>
                <participants group_id="P3" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Diabetic glucose level or HbA1C&gt;=6.5%</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change of residence or other commitments</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Variable Dose Group of Aripiprazole</title>
          <description>Aripiprazole 3~15 mg were administered orally once daily. During the first week, 3 mg was administered once daily. Thereafter, each week, a dose increase of 3 mg per day was carried out</description>
        </group>
        <group group_id="B2">
          <title>Fixed Dose Group of Aripiprazole</title>
          <description>Aripiprazole 3 mg were administered orally once daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo Group</title>
          <description>Placebo were administered orally once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="194"/>
            <count group_id="B2" value="197"/>
            <count group_id="B3" value="195"/>
            <count group_id="B4" value="586"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.1" spread="9.6"/>
                    <measurement group_id="B2" value="39.2" spread="9.1"/>
                    <measurement group_id="B3" value="38.7" spread="9.2"/>
                    <measurement group_id="B4" value="38.7" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
        <description>The change in MADRS total score from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period by covariance analysis, and compared the aripiprazole variable dose group with the placebo group as well as the aripiprazole fixed dose group with the placebo group.
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.
The questionnaire includes questions on the following symptoms
1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts</description>
        <time_frame>Baseline (the end of the SSRI/SNRI treatment period), at completion of administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Variable Dose Group of Aripiprazole</title>
            <description>Aripiprazole 3~15 mg were administered orally once daily. During the first week, 3 mg was administered once daily. Thereafter, each week, a dose increase of 3 mg per day was carried out</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose Group of Aripiprazole</title>
            <description>Aripiprazole 3 mg were administered orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>Placebo were administered orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The change in MADRS total score from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period by covariance analysis, and compared the aripiprazole variable dose group with the placebo group as well as the aripiprazole fixed dose group with the placebo group.
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.
The questionnaire includes questions on the following symptoms
1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts</description>
          <units>Rating score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="0.6"/>
                    <measurement group_id="O2" value="-10.5" spread="0.6"/>
                    <measurement group_id="O3" value="-7.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MADRS Response Rate</title>
        <description>The percentage of subjects with a decrease in MADRS total score of 50% or more, from the end of the SSRI/SNRI treatment period to the end of the placebo-controlled, double-blind treatment period (or withdrawal).</description>
        <time_frame>Baseline (the end of the SSRI/SNRI treatment period), at completion of administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Variable Dose Group of Aripiprazole</title>
            <description>Aripiprazole 3~15 mg were administered orally once daily. During the first week, 3 mg was administered once daily. Thereafter, each week, a dose increase of 3 mg per day was carried out</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose Group of Aripiprazole</title>
            <description>Aripiprazole 3 mg were administered orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>Placebo were administered orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>MADRS Response Rate</title>
          <description>The percentage of subjects with a decrease in MADRS total score of 50% or more, from the end of the SSRI/SNRI treatment period to the end of the placebo-controlled, double-blind treatment period (or withdrawal).</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="42.1"/>
                    <measurement group_id="O3" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Sheehan Disability Scale (SDISS)</title>
        <description>The endpoint evaluated the change in SDISS from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period.
The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).</description>
        <time_frame>Baseline (the end of the SSRI/SNRI treatment period), at completion of administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Variable Dose Group of Aripiprazole</title>
            <description>Aripiprazole 3~15 mg were administered orally once daily. During the first week, 3 mg was administered once daily. Thereafter, each week, a dose increase of 3 mg per day was carried out</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dose Group of Aripiprazole</title>
            <description>Aripiprazole 3 mg were administered orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>Placebo were administered orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Sheehan Disability Scale (SDISS)</title>
          <description>The endpoint evaluated the change in SDISS from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period.
The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).</description>
          <units>Rating score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.11"/>
                    <measurement group_id="O2" value="-0.96" spread="0.11"/>
                    <measurement group_id="O3" value="-0.46" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Variable Dose Group of Aripiprazole</title>
          <description>Aripiprazole 3~15 mg were administered orally once daily. During the first week, 3 mg was administered once daily. Thereafter, each week, a dose increase of 3 mg per day was carried out</description>
        </group>
        <group group_id="E2">
          <title>Fixed Dose Group of Aripiprazole</title>
          <description>Aripiprazole 3 mg were administered orally once daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo Group</title>
          <description>Placebo were administered orally once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA(14.1)J</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Post-Traumatic Neck Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Traffic Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage Subcutaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA(14.1)J</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="197"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="194"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="197"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="197"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="197"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Salivary Hypersecretion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="194"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="194"/>
                <counts group_id="E2" events="31" subjects_affected="30" subjects_at_risk="197"/>
                <counts group_id="E3" events="31" subjects_affected="28" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="194"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="197"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Blood Triglycerides Increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="197"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Rigidity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="71" subjects_at_risk="194"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="197"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="197"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="194"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="197"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="194"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="197"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="197"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Terminal Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research and Development</name_or_title>
      <organization>Otsuka Pharmaceutical Co., Ld.</organization>
      <phone>+81-3-6361-7366</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

